Diligence memo · auto-generated · as of July 2, 2026
Pelage Pharmaceuticals, Inc.
Pelage Pharmaceuticals, Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Pelage Pharmaceuticals, Inc. operates in Pharmaceuticals, based in LOS ANGELES.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Pelage Pharmaceuticals, Inc. has raised $151M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $120M on 2025-09-18.
Most recent recorded round closed around 2025-09-18.
Valuation (modeled)modeled
Provath models Pelage Pharmaceuticals, Inc. at approximately $902M (range $571M–$1.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.00× the median modeled value of Series D+ Pharmaceuticals companies in 2025–2027 (7 peers) — value vs value, same stage and era. Within the normal band (100% of peer median) for its niche.
Financing rhythm & timingmixed
Historic cadence: a new round about every 13 months.
Last raise 9 mo ago; this sector typically re-raises about every 13 months.
Raising on or ahead of the sector's normal rhythm.
The last round stepped up 8.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 87% of those peers.
Closest niche peers: DBV Technologies S.A., Galecto, Inc., NovaBay Pharmaceuticals, Inc., Triana Biomedicines, Inc., Quoin Pharmaceuticals, Ltd..
Peoplefiled
7 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.